Relevance of Ki-67 and prognostic factors for recurrence/progression of gonadotropic adenomas after first surgery

European Journal of Endocrinology

Volumn 157, Issue 2, 2007, Pages 141-147

  Dubois, S ^a   Guyetant S ^a   Menei, P ^a   Rodien, P ^a,b   Illouz, F ^a   Vielle, B ^a   Rohmer, V ^a,b  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ D'ANGERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GONADECTOMY; GROWTH HORMONE DEFICIENCY; HAZARD RATIO; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VOLUME;

ADENOMA; ADULT; AGED; AGING; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; GONADOTROPINS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PITUITARY NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 34547729637     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0099     Document Type: Article

References (54)

1. Black PM, Hsu DW & Klibanski A. Hormone production in clinically non functioning pituitary adenomas. Journal of Neurosurgery 1987 66 244-250.
2. Thapar K, Kovacs F & Scheithauer BW. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody Neurosurgery 1996 38 99-107.
3. Dekkers OM, Hammer S, de Keizer RJ, Roelfsema F, Shutte PJ, Smit JW, Romijn JA & Pereira AM. The natural course of non-functioning pituitary macroadenomas. European Journal of Endocrinology 2007 156 217-224.
4. Ebersold MJ, Quast LM & Laws ER Jr. Long term results in transphenoidal removal of non functioning pituitary adenomas. Journal of Neurosurgery 1986 64 713-719.
5. Oruçkaptan MR, Senmevsim O & Ozcan OE. Pituitary adenomas: results of 684 surgically treated patients and review of the literature. Surgical Neurology 2000 53 211-219.
6. Sassolas G, Trouillas J & Treluyer C. Management of non functioning pituitary adenomas. Acta Endocrinologica 1993 129 21-26.
7. Dekkers OM, Pereira AM, Roelfsema F, Voormolen JH, Neelis KJ, Schroijen MA, Smit JW & Romijn JA. Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma. Journal of Clinical Endocrinology and Metabolism 2006 91 1796-1801.
8. Greenman Y, Tordjman K, Somjen D, Reider-Groswasser I, Kohen F, Ouaknine G & Stern N. The use of beta-subunits of gonadotropin hormones in the follow-up of clinically non-functioning pituitary tumours. Clinical Endocrinology 1998 49 185-190.
9. Ekramullah M, Saitoh Y & Arita N. The correlation of Ki-67 staining indices with tumor doubting times in regrowing non-functioning pituitary adenomas. Acta Neurochirurgica 1996 138 1449-1455.
10. Rauhut F, Clar HE & Bamberg M. Diagnostic criteria in pituitary tumour recurrence - combined modality of surgery and radio-therapy. Acta Neurochirurgica 1986 80 73-78.
11. Greenman Y, Ouaknine G, Veshchev I, Reider-Groswasser II, Segev Y & Stern N. Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth. Clinical Endocrinology 2003 58 763-769.
12. Brown DC & Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology 1990 17 489-503.
13. Gerdes J, Schwab V & Lemke H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. International Journal of Cancer 1983 31 13-20.
14. Gerdes J, Lemke H & Baisch H. Cell type analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. Journal of Immunology 1984 133 1710-1715.
15. Gerdes J. An immunohistological method for estimating cell growth fractions in rapid histopathological diagnosis during surgery. International Journal of Cancer 1985 35 169-171.
16. Gerdes J, Li L & Schlueter C. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. American Journal of Pathology 1991 138 867-873.
17. Hentschel SJ, McCutcheon IE & Moore W p53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas. Canadian Journal of Neurological Sciences 2003 30 215-219.
18. Honegger J, Prettin C & Feuerhake F. Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. Journal of Neurosurgery 2003 99 674-679.
19. Schreiber S, Saeger W & Lüdecke DK. Proliferation markers in different types of clinically non-secreting pituitary adenomas. Pituitary 1999 1 213-220.
20. Turner HE & Wass JA. Are markers of proliferation valuable in the histological assessment of pituitary tumours? Pituitary 1999 1 147-151.
21. Croue A, Beldent V & Rousselet MC. Contribution of immunohistochemistry, electron microsopy, and cell culture to the characterisation of nonfunctioning pituitary adenomas: a study of 40 cases. Human Pathology 1992 23 1332-1339.
22. Hsu DW, Hakim F & Biller BMK. Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. Journal of Neurosurgery 1993 78 753-761.
23. Knosp E, Kitz K & Perncczky A. Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery 1989 25 927-930.
24. Mastronardi L, Guiducci A & Puzzilli F. Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas. BMC Cancer 2001 1 12.
25. Burger PC, Shibata T & Kleihues P. The use of the monoclonal antibody Ki-67 in the identification of proliferating cells. American Journal of Surgical Pathology 1986 10 611-617.
26. Charpin C, Andrac L & Vacheret H. Multiparametric evaluation (SAMBA) of growth fraction (monoclonal Ki-67) in breast carcinoma tissue sections. Cancer Research 1988 48 4368-4374.
27. Hopf NJ, Bremm J & Bold J. Image analysis of proliferating cells in tumors of the human nervous system: an immunohistological study with the monoclonal antibody Ki-67. Neurosurgery 1994 35 917-923.
28. Keshgegian AA & Cnaan A. Proliferation markers in breast carcinoma. Mitotic figure count, S phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. American Journal of Clinical Pathology 1995 104 42-49.
29. Kontogeorgos G. Predictive markers of pituitary adenoma behavior. Neuroendocrinology 2006 83 179-188.
30. Mizoue T, Kawamoto H & Arita K. MIB-1 immunopositivity is associated with rapid regrowth of pituitary adenomas. Acta Neurochirurgica 1997 139 426-432.
31. Pizarro CB, Olivieira MC & Coutinho LB. Measurement of Ki-67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody. Brazilian Journal of Medical and Biological Research 2004 37 235-243.
32. Shibuya M, Saito F & Miwa T. Histochemical study of pituitary adenomas with Ki-67 and anti-DNA polymerase alpha monoclonal antibodies, bromodeoxy-uridine labeling, and nucleolar organizer region counts. Acta Neuropathologica 1992 84 178-183.
33. Tanaka Y, Hongo K & Tada T. Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlation among tumor volume doubling time, patient age, and MIB-1 index. Journal of Neurosurgery 2003 98 359-365.
34. Zornitzki T, Knobler H & Nass D. Increased MIB-1/Ki-67 index as a predictor of an aggressive course in a case of prolactinoma. Hormone Research 2004 61 111-116.
35. Espay AJ, Azzarelli B & Williams L. Recurrence in pituitary adenomas in childhood and adolescence. Journal of Child Neurology 2001 16 364-367.
36. Losa M, Franzin A & Mangili F. Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long term follow-up results. Neurosurgery 2000 47 1313-1319.
37. Yonezawa K, Tamaki N & Kokunai T. Clinical features and growth fractions of pituitary adenoma. Surgical Neurology 1997 48 494-500.
38. Nagashima T, De Armond SJ & Murovic J. Immunocytochemical demonstration of S-Phase cells by anti-bromodeoxyuridine monoclonal antibody in human brain tumor tissue. Acta Neuropathologica 1985 67 155-159.
39. Landolt AM, Taichiro S & Kleihues P. Growth rate of human pituitary adenomas. Journal of Neurosurgery 1987 67 803-806.
40. Carboni P Jr, Detta A & Hitchcock ER. Pituitary adenoma proliferative indices and risk of recurrence. British Journal of Neurosurgery 1992 6 33-40.
41. Pegolo G, Buckwalter JG & Weiss MH. Pituitary adenomas. Correlation of the cytologic appearance with biologic behavior. Acta Cytologica 1995 39 887-892.
42. Heitz PhU, Komminoth P, Perren A, Klimstra DS, Dayal Y, Bordi C, Lechago J, Centeno BA & Klöppel G. Pancreatic endocrine tumours: introduction. In World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs, ch 4, pp 177-182. Eds R Lloyd, R Dehellis, P Heitz and C Eng. Lyon: IARC Press, 2004.
43. Nakabayashi H, Sunada I & Hara M. Immunohistochemical analyses of cell cycle-related proteins, apoptosis, and proliferation in pituitary adenomas. Journal of Histochemistry and Cytochemistry 2001 49 1193-1194.
44. Turner HE, Nagy Z & Gatter KC. Angiogenesis in pituitary gland. Journal of Clinical Endocrinology and Metabolism 2000 85 1159-1162.
45. Turner HE, Nagy Z & Gatter KC. Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumour behaviour. British Journal of Cancer 2000 82 1441-1445.
46. Turner HE, Nagy Z & Esiri MM. Role of matrix metalloproteinase 9 in pituitary tumor behavior. Journal of Clinical Endocrinology and Metabolism 2000 85 2931-2935.
47. Semba S, Han SY & Ikeda H. Frequent nuclear accumulation of beta-catenin in pituitary adenoma. Cancer 2000 91 42-48.
48. Yoshino A, Katayama Y & Fukushima T. Telomerase activity in pituitary adenomas: significance of telomerase expression in predicting pituitary adenoma recurrence. Journal of Neuro-Oncology 2003 63 155-162.
49. Erfwith EM, Bulow B & Mikoczy Z. Incidence of a second tumor in hypopituitary patients operated for pituitary tumors. Journal of Clinical Endocrinology and Metabolism 2001 86 659-662.
50. Mindermann T & Wilson CB. Pediatric pituitary adenomas. Neurosurgery 1995 36 259-269.
51. Scheithauer BW, Jaap AJ, Horvath E, Kovacs K, Lloyd RV, Meyer FB, Laurs ER Jr & Young WF Jr. Clinically silent corticotroph tumors of the pituitary gland. Neurosurgery 2004 47 723-729.
52. Bradley KJ, Wass JA & Turner BE. Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently. Clinical Endocrinology 2003 58 59-64.
53. Mavrakis AN & Tritos NA. Diagnostic and therapeutic approach to pituitary incidentaloma. Endocrine Practice 2004 10 438-444.
54. Buurman H & Saeger W. Subclinical adenomas in post mortem pituitaries: classification and correlation to clinical data. European Journal of Endocrinology 2006 154 753-758.